President Tinubu argues that Nigeria must manufacture far more of its own medicines and medical equipment, writing in an opinion column published this week that dependence on imported health products remains “unacceptably high” while Nigerians continue to travel abroad for treatment.
The piece frames health care as an economic project rather than a social one.
The argument rests on a straightforward economic claim: a country of Nigeria’s size should keep more of what its citizens spend on health inside its own economy. “A country with our demographic strength should be securing a greater share of the production, employment and specialist services supported by what our people spend on their health,” Tinubu wrote.
Tinubu states that exchange-rate movements can push essential medicines beyond a household’s reach, that supply disruptions far from Nigerian shores can empty hospital shelves, and that money spent on treatment abroad sustains expertise and facilities in other countries—capacity he says Nigeria must instead build at home.
The Bottom Line
- Tinubu’s industrial policy for health care runs through two existing programs: the Presidential Initiative for Unlocking the Healthcare Value Chain (PVAC), launched in October 2023, and the Nigeria Health Sector Renewal Investment Initiative (NHSRII), launched in December 2023.
- The stated targets are domestic production of essential health products, better care inside Nigeria, and quality employment across the sector, funded by Nigerian and international investment.
- The Federal Government, states and development partners have signed a compact committing to a common reform program, according to the article.
Why the President Is Writing About Supply Chains
Nigeria already has an established pharmaceutical industry base, highly skilled health professionals and a substantial domestic market—Tinubu’s own inventory of national assets. What the country lacks, by his account, is the share of production those assets should support. More of what Nigerians spend on their health, he writes, should flow to local businesses and jobs.
The market logic is familiar to anyone who has watched a currency depreciation reprice an import-dependent economy. When a household’s medicine bill is denominated in dollars and its income in naira, the exchange rate becomes a health variable. Tinubu makes that link explicitly: changes in the exchange rate “can put essential medicines beyond a household’s reach,” he wrote in the column published.
But the balance sheet tells a different story for the state itself. Illness that keeps a worker home, a child out of school or a small business owner away from work costs the economy beyond the clinic, Tinubu argues, and a serious illness can consume years of a family’s savings. He positions health spending as human capital accumulation—both a cause and a consequence of productivity.
Programs Drive Health Care Investment
The machinery predates this week’s column. In October 2023, Tinubu established the Presidential Initiative for Unlocking the Healthcare Value Chain, or PVAC, to bring Nigerian and international investment into domestic manufacturing and healthcare services. In December 2023, he launched the NHSRII to give effect to the health commitments of the Renewed Hope Agenda, with a stated purpose of saving lives and reducing the physical and financial hardship caused by illness.
| Program | Launched | Stated Focus |
|---|---|---|
| PVAC | October 2023 | Investment into domestic manufacturing and healthcare services |
| NHSRII | December 2023 | Health commitments of the Renewed Hope Agenda; governance, services, domestic production, emergency preparedness |
| Reform compact | Accompanying NHSRII | Common program binding Federal Government, states and development partners |
The two initiatives are designed to work in the same direction. Under the accompanying compact, the Federal Government, states and development partners committed to a common program of reform, so that investment in industry serves the same national purpose as investment in clinics and hospitals.
Coordination as the Real Product
Tinubu’s case for a presidential initiative is less about money than about alignment. Health, finance, industry and investment decisions sit in different ministries; a presidential initiative, he writes, brings them into a common program. Manufacturers, he argues, should be able to plan with confidence in the rules under which they operate, and investors should find government institutions working toward the same objectives.
That coordination matters most where capital requirements are heaviest. A project that needs substantial capital and several years to reach commercial scale—a pharmaceutical plant, for instance—cannot survive policy whiplash. Tinubu’s framing acknowledges the problem without naming a specific facility, timeline or investment figure.
International cooperation sits at the center of the pitch. “Nigeria welcomes investors who bring capital, expertise and a long-term commitment to production here,” Tinubu wrote, positioning the country’s market size as the draw for outside capital rather than relying on public spending alone.
What the Column Does Not Answer
The article is a statement of ambition, not a budget. It names no production targets, no capital commitments, no deadlines and no metrics by which Nigerians should judge whether PVAC and NHSRII are delivering. Tinubu offers the outcome he expects—dependable care, more affordable treatment, opportunities to earn a decent living—without the intermediate numbers.
What is verifiable so far is the institutional record: two initiatives launched in late 2023, a multi-level reform compact, and a presidential argument that health care belongs on the industrial policy agenda. Whether domestic manufacturing capacity has actually expanded since October 2023 is a question the column raises but does not answer.
“Nigerians should expect these investments to deliver dependable care, more affordable treatment and opportunities to earn a decent living,” Tinubu wrote.
Disclaimer: The information provided in this article is for educational and informational purposes only and does not constitute financial advice.